Indran S K
Department of Psychiatry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur.
Singapore Med J. 1995 Apr;36(2):189-90.
The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia. Twenty patients who satisfied DSM III R criteria for depressive disorders and scored more than 16 on the Hamilton Rating Depression Score at the initial interview were recruited into this open study. The primary diagnosis of 4 patients was later ascertained to be panic disorder(2), schizophrenia(1) and social phobia(1). Patients rated themselves as improved by first follow up (7-14 days), and rated their depression as very mild to mild by the third follow up visit (ie at a mean of 46 days). Side effects were minimal and compliance good.
本研究的目的是描述吗氯贝胺治疗马来西亚大学门诊抑郁症的初步经验。20名符合DSM III R抑郁症标准且在初次访谈时汉密尔顿抑郁量表评分超过16分的患者被纳入这项开放性研究。后来确定4名患者的初步诊断为惊恐障碍（2例）、精神分裂症（1例）和社交恐惧症（1例）。患者在首次随访（7 - 14天）时自评有所改善，在第三次随访时（即平均46天时）将自己的抑郁程度评为非常轻微至轻度。副作用极小，依从性良好。
